newsfilter
← Latest News
PR Newswire·

MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other Dementias

Acquisition will strengthen MYND's psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer's disease. VANCOUVER, BC, Dec. 17, 2021 /PRNewswire/ - Further to news release